Compass Pathways Phase 2 Psilocybin Results far from Spectacular
Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks
compass
Patent Controversies in Psychedelics
What investors need to know about the intellectual property behind medicine’s next big growth area
Math Over Myth: These Psychedelic Stocks Made Confirmed Bottoms in Q3
Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS, Cybin, GH Research, Mindset, Numinus, and more
Math Over Myth: September Psychedelic Stock News Roundup
Track the monthly performance of the psychedelic stock sector with our Math over Myth Stock News Roundup
Math Over Myth: Spotlight on Psychedelic Stocks ATAI & COMPASS
If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways
Compass Pathways Sued for Stealing Trade Secrets
Compass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property
The Battle for Psychedelic Patents
Psychedelic companies rely on novel patents to boost their value, but many players in the space are chasing the same IP
This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Compass Pathways Psilocybin Patent Upheld
Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.
End of content
End of content